Keilholz U, Scheibenbogen C, Brado M, Georgi P, Maclachlan D, Brado B, Hunstein W
Department of Internal Medicine V, University of Heidelberg, Germany.
Eur J Cancer. 1994;30A(1):103-5. doi: 10.1016/s0959-8049(05)80028-0.
A phase lb trial of a novel regional approach to adoptive immunotherapy is reported. Patients with liver metastases received continuous high-dose infusion of interleukin-2 (IL-2) into the splenic artery or intravenous infusion with subsequent transfer of lymphokine-activated killer (LAK) cells into the portal vein or the hepatic artery. Trafficking studies revealed homogeneous distribution of the LAK cells within the liver. The usual side-effects of IL-2 and LAK cells occurred without limiting liver toxicity. One partial (7+ months) and two complete responses (36 and 26+ months) were observed in 9 patients with metastases from cutaneous melanoma. None of 6 patients with metastases from ocular melanoma responded.
报告了一项采用新型区域方法进行过继性免疫治疗的1b期试验。肝转移患者接受脾动脉持续高剂量输注白细胞介素-2（IL-2）或静脉输注，随后将淋巴因子激活的杀伤细胞（LAK细胞）转移至门静脉或肝动脉。示踪研究显示LAK细胞在肝脏内分布均匀。出现了IL-2和LAK细胞常见的副作用，但未出现肝脏毒性受限的情况。在9例皮肤黑色素瘤转移患者中观察到1例部分缓解（7 +个月）和2例完全缓解（36和26 +个月）。6例眼黑色素瘤转移患者均无反应。
